Wellness Wire Kansas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Kansas.

Press releases published on September 30, 2026

Sep. 30, 2026

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Indeterminate GlobeNewswire

Sep. 30, 2026

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire

Sep. 30, 2026

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire

Sep. 30, 2026

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire

Sep. 30, 2026

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Indeterminate GlobeNewswire

Sep. 30, 2026

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Indeterminate GlobeNewswire

Sep. 30, 2026

DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform

Indeterminate GlobeNewswire

Sep. 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Indeterminate GlobeNewswire

Sep. 30, 2026

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Indeterminate GlobeNewswire

Sep. 30, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Indeterminate GlobeNewswire

Sep. 30, 2026

CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH

Indeterminate GlobeNewswire

Sep. 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire

Sep. 30, 2026

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Indeterminate GlobeNewswire

Sep. 30, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Indeterminate GlobeNewswire

Sep. 30, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Indeterminate GlobeNewswire

Sep. 30, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

Indeterminate GlobeNewswire

Sep. 30, 2026

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire

Sep. 30, 2026

More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research

Indeterminate GlobeNewswire